SPY414.92-5.67 -1.35%
DIA332.96-5.20 -1.54%
IXIC14,030.38-130.97 -0.92%

BRIEF-Liquidia Resubmits New Drug Application For LIQ861 Inhalation Powder

05/10/2021 07:27
BRIEF-Liquidia Resubmits New Drug Application For LIQ861 Inhalation Powder

- Liquidia Corp LQDA.O:

  • LIQUIDIA RESUBMITS NEW DRUG APPLICATION FOR LIQ861 (TREPROSTINIL) INHALATION POWDER FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

  • LIQUIDIA CORP - RESUBMITTED NDA INCLUDES ADDITIONAL INFORMATION AND CLARIFICATION ON CMC PERTAINING TO DRUG PRODUCT, DATA ON DEVICE BIOCOMPATIBILITY

  • LIQUIDIA CORP - ANTICIPATES THAT FDA WILL CLASSIFY RESUBMITTED NDA, IF ACCEPTED, AS A CLASS 2 RESUBMISSION

Source text for Eikon: ID:nGNX3XgZCx

Further company coverage: LQDA.O


(([email protected];))